Zydus’ specialty pipeline remains the key focus with Desidustat in China, Saroglitazar and Nufymco launches in the US. The management said the specialty business is expected to see a meaningful ramp-up from FY28 onwards.
Zydus’ specialty pipeline remains the key focus with Desidustat in China, Saroglitazar and Nufymco launches in the US. The management said the specialty business is expected to see a meaningful ramp-up from FY28 onwards.